Using PARP inhibitors to prevent transmission of a BRCA mutation seems like an exceedingly risky strategy, when pre-implantation diagnosis or selective terminat

Using PARP inhibitors to prevent transmission of a BRCA mutation seems like an exceedingly risky strategy, when pre-implantation diagnosis or selective termination are effective and have pretty well-defined risks. Messing with DNA damage detection and repair machinery is probably not something you want to do in gametes. Even if this worked in mice, it is difficult for me to imagine how a trial could even be done to allow it to be approved for human use.